ArticleAdvances in radiation oncology
Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.Journal of neuro-oncology · 2023Pooled it
- Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02.ESMO open · 2026Article
- Article
- Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study.Clinical and translational radiation oncology · 2025Article
- Clinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group Registry.Advances in radiation oncology · 2025Article
- Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.Journal of neuro-oncology · 2025Article
- Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care.Frontiers in oncology · 2025Article
- Article
- Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center.Journal of neuro-oncology · 2024Article
- Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation.Radiation oncology journal · 2024Article
- Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.Journal of neuro-oncology · 2023Article
- Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma.Journal of personalized medicine · 2023Article
- Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.Neuro-oncology practice · 2022Article
- Optimising tumour coverage and organ at risk sparing for hypofractionated re-irradiation in glioblastoma.Physics and imaging in radiation oncology · 2022Article
- Re-irradiation for high-grade gliomas: Has anything changed?World journal of clinical oncology · 2021Review
- High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Current status and recent advances in reirradiation of glioblastoma.Radiation oncology (London, England) · 2021Review
- Research progress on mechanism and dosimetry of brainstem injury induced by intensity-modulated radiotherapy, proton therapy, and heavy ion radiotherapy.European radiology · 2020Review
- Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival.Neuro-oncology practice · 2019Article
- Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation.Radiation oncology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReirradiation for recurrent glioma remains controversial without knowledge of optimal patient selection, dose, fractionation, and normal tissue tolerances. We retrospectively evaluated outcomes and toxicity after conventionally fractionated reirradiation for recurrent high-grade glioma, along with the impact of concurrent chemotherapy. METHODS AND MATERIALS: We conducted a retrospective review of patients reirradiated for high-grade glioma recurrence between 2007 and 2016 (including patients with initial low-grade glioma). Outcome metrics included overall survival (OS), prognostic factors for survival, and treatment-related toxicity.
resultsPatients (n = 118; median age 47 years; median Karnofsky performance status score: 80) were re-treated at a median of 28 months (range, 5-214 months) after initial radiation therapy. The median reirradiation dose was 41.4 Gy (range, 12.6-54.0 Gy) to a median lesion volume of 202 cm
conclusionsSalvage reirradiation, even at doses >41.4 Gy in conventional fractionation, along with chemotherapy, was safe and well tolerated with meaningful survival duration. These data provide information that may be useful in implementing safe reirradiation treatments for appropriately selected patients and guiding future studies to define optimal reirradiation doses, maximal safe doses to critical structures, and the role of systemic therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.